Within their intermediate-risk PCa population, 8.5% (6/71) of men had bone metastases on PSMA PET/CT, which could be attributed to [18F]F-PSMA-1007’s higher rates of nonspecific bone lesions [25,26,27]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.